Sana Biotechnology (NASDAQ:SANA) and Passage Bio (NASDAQ:PASG) Head to Head Analysis

Passage Bio (NASDAQ:PASGGet Free Report) and Sana Biotechnology (NASDAQ:SANAGet Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Earnings & Valuation

This table compares Passage Bio and Sana Biotechnology’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Passage Bio N/A N/A -$102.06 million ($1.53) -0.81
Sana Biotechnology N/A N/A -$283.26 million ($1.53) -5.10

Sana Biotechnology is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Passage Bio has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Passage Bio and Sana Biotechnology, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Passage Bio 0 0 3 0 3.00
Sana Biotechnology 0 1 3 0 2.75

Passage Bio presently has a consensus price target of $9.00, indicating a potential upside of 625.81%. Sana Biotechnology has a consensus price target of $11.67, indicating a potential upside of 49.38%. Given Passage Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Passage Bio is more favorable than Sana Biotechnology.


This table compares Passage Bio and Sana Biotechnology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Passage Bio N/A -68.53% -51.64%
Sana Biotechnology N/A -88.13% -47.16%

Insider & Institutional Ownership

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 4.3% of Passage Bio shares are owned by insiders. Comparatively, 31.1% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Passage Bio beats Sana Biotechnology on 5 of the 9 factors compared between the two stocks.

About Passage Bio

(Get Free Report)

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

About Sana Biotechnology

(Get Free Report)

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with's FREE daily email newsletter.